{
    "organizations": [],
    "uuid": "6a48f9b2027fd03fb26b9d8b686615593e6b022f",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/04/globe-newswire-genocea-to-host-first-quarter-2018-financial-results-conference-call-webcast-on-may-10-2018-at-9-a-m-et.html",
    "ord_in_thread": 0,
    "title": "Genocea to Host First Quarter 2018 Financial Results Conference Call & Webcast on May 10, 2018 at 9 a.m. ET",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CAMBRIDGE, Mass., May 04, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. ( NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, May 10, 2018 at 9:00 a.m. ET to discuss financial results for the first quarter of 2018. Genocea management will also provide an update on the Company's recent progress and upcoming milestones.\nInterested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 3866939. To join the live webcast, please visit the investor relations section of the Genocea website at http://ir.genocea.com .\nA webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.\nAbout Genocea Biosciences, Inc.\nGenocea's mission is to help conquer cancer by designing and delivering targeted vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLASâ„¢, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. For more information, please visit www.genocea.com .\nContact:\nJennifer LaVin\n617-715-6687\nJennifer.lavin@genocea.com\nSource:Genocea Biosciences, Inc.",
    "published": "2018-05-04T16:04:00.000+03:00",
    "crawled": "2018-05-04T18:14:18.016+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "cambridge",
        "may",
        "globe",
        "newswire",
        "genocea",
        "bioscience",
        "nasdaq",
        "gnca",
        "biopharmaceutical",
        "company",
        "developing",
        "neoantigen",
        "cancer",
        "vaccine",
        "today",
        "announced",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "thursday",
        "may",
        "et",
        "discus",
        "financial",
        "result",
        "first",
        "quarter",
        "genocea",
        "management",
        "also",
        "provide",
        "update",
        "company",
        "recent",
        "progress",
        "upcoming",
        "milestone",
        "interested",
        "participant",
        "may",
        "access",
        "conference",
        "call",
        "dialing",
        "domestic",
        "international",
        "refer",
        "conference",
        "id",
        "number",
        "join",
        "live",
        "webcast",
        "please",
        "visit",
        "investor",
        "relation",
        "section",
        "genocea",
        "website",
        "http",
        "webcast",
        "replay",
        "available",
        "genocea",
        "website",
        "beginning",
        "approximately",
        "two",
        "hour",
        "event",
        "archived",
        "day",
        "genocea",
        "bioscience",
        "genocea",
        "mission",
        "help",
        "conquer",
        "cancer",
        "designing",
        "delivering",
        "targeted",
        "vaccine",
        "immunotherapy",
        "traditional",
        "immunotherapy",
        "discovery",
        "method",
        "largely",
        "used",
        "predictive",
        "method",
        "propose",
        "cell",
        "target",
        "antigen",
        "genocea",
        "developed",
        "proprietary",
        "technology",
        "platform",
        "identify",
        "clinically",
        "relevant",
        "antigen",
        "cell",
        "based",
        "actual",
        "human",
        "immune",
        "response",
        "genocea",
        "using",
        "atlas",
        "application",
        "develop",
        "neoantigen",
        "cancer",
        "vaccine",
        "also",
        "exploring",
        "partnership",
        "opportunity",
        "general",
        "cancer",
        "vaccine",
        "vaccine",
        "targeting",
        "cancer",
        "caused",
        "virus",
        "genocea",
        "expects",
        "begin",
        "clinical",
        "development",
        "first",
        "neoantigen",
        "cancer",
        "vaccine",
        "information",
        "please",
        "visit",
        "contact",
        "jennifer",
        "lavin",
        "source",
        "genocea",
        "bioscience",
        "inc"
    ]
}